5-(trimethylstannyl)pyrazin-2-amine | 321957-61-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(trimethylstannyl)pyrazin-2-amine
• 英文别名: 5-(Trimethylstannanyl)-2-pyrazinamine；5-trimethylstannylpyrazin-2-amine
• CAS: 321957-61-3
• 化学式: C₇H₁₃N₃Sn
• 分子量: 257.91
• InChiKey: ZDFLQMINHCPBOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(trimethylstannyl)pyrazin-2-amine 、 1,1-dimethylethyl 7-(bromomethyl)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 在 双三苯基磷二氯化钯 氩 、 Ethyl acetate pentane 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 1,1-dimethylethyl 7-[(5-amino-2-pyrazinyl)methyl]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate
  参考文献：
  名称：

  TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR

  摘要：

  本发明涉及具有药理活性的新型苯并氮杂环衍生物，其制备方法，包含它们的组合物以及它们在神经系统和精神障碍治疗中的应用。

  公开号：

  US20070208005A1
• 作为产物：
  描述：

  2-氨基-5-溴吡嗪 、 六甲基二锡 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 以18 %的产率得到5-(trimethylstannyl)pyrazin-2-amine
  参考文献：
  名称：

  Discovery of Potent and Selective Dual Leucine Zipper Kinase/Leucine Zipper-Bearing Kinase Inhibitors with Neuroprotective Properties in In Vitro and In Vivo Models of Amyotrophic Lateral Sclerosis

  摘要：

  DOI：

  10.1021/acs.jmedchem.2c01056

文献信息

• [EN] SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRIDINE EN TANT QUE MODULATEURS DE CRAC
  申请人：LUPIN LTD

  公开号：WO2013164769A1

  公开（公告）日：2013-11-07

  The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release- activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I)and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.

  本发明涉及式(I)描述的化合物以及其中医药可接受的盐，这些化合物能够调节钙释放激活钙(CRAC)通道的活性。该发明还描述了式(I)的化合物以及包含这些化合物的药物组合物，用于治疗、管理和/或减轻与调节钙释放激活钙(CRAC)通道相关联的疾病、障碍、综合征或状况的严重性。
• [EN] TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H 3 RECEPTOR<br/>[FR] TETRAHYDROBENZAZEPINES UTILISEES COMME ANTAGONISTES ET/OU AGONISTES INVERSES DU RECEPTEUR H3 DE L'HISTAMINE
  申请人：GLAXO GROUP LTD

  公开号：WO2006018260A1

  公开（公告）日：2006-02-23

  The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的新型苯并哌啶衍生物，其制备方法，含有它们的组合物，以及它们在治疗神经和精神疾病中的用途。
• OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS
  申请人：Irlapati Nageswara Rao

  公开号：US20130225600A1

  公开（公告）日：2013-08-29

  The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

  本发明涉及式（I）的化合物及其制备方法，这些化合物对于治疗、预防和/或管理与CRAC调节相关的疾病、紊乱、综合症或状况是有用的。本发明还涉及使用式（I）的化合物治疗、预防、管理和/或减轻与CRAC调节相关的疾病、紊乱、综合症或状况的方法。
• Oxazoline and isoxazoline derivatives as CRAC modulators
  申请人：Irlapati Nageswara Rao

  公开号：US09169242B2

  公开（公告）日：2015-10-27

  The present invention relates to compounds that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC and to processes for preparing these compounds. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC by these compounds.

  本发明涉及用于治疗、预防和/或管理与CRAC调节相关的疾病、障碍、综合征或情况的化合物，并涉及制备这些化合物的过程。此外，本发明还涉及通过这些化合物治疗、预防、管理和/或减轻与CRAC调节相关的疾病、障碍、综合征或情况的方法。
• OXAZOLE AND ISOXAZOLE CRAC MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20160022673A1

  公开（公告）日：2016-01-28

  The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

  本发明涉及公式（I）的化合物及其制备方法，用于治疗、预防和/或管理与CRAC调节相关的疾病、疾病、综合征或病况。本发明还涉及使用公式（I）的方法来治疗、预防、管理和/或减轻与CRAC调节相关的疾病、疾病、综合征或病况。